Cholic acid for hepatic steatosis in patients with lipodystrophy: A randomized, controlled trial

European Journal of Endocrinology

Volumn 168, Issue 5, 2013, Pages 771-778

  Ahmad, Zahid ^a,b   Subramanyam, Lalitha ^a,d   Szczepaniak, Lidia ^b,c   Simha, Vinaya ^a,e   Adams Huet, Beverley ^a,b   Garg, Abhimanyu ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d North Texas Associates END   (United States)

^e MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLIC ACID; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EZETIMIBE; FIBRIC ACID DERIVATIVE; FISH OIL; GAMMA GLUTAMYLTRANSFERASE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; NICOTINIC ACID; PLACEBO; SULFONYLUREA; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FATTY LIVER; FEMALE; FLATULENCE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; LIPODYSTROPHY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; CHOLIC ACID; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FATTY LIVER; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; LIPODYSTROPHY; LIVER; MALE; MIDDLE AGED; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84877123938     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-0969     Document Type: Article

References (46)

1. Garg A. Acquired and genetic lipodystrophies. New England Journal of Medicine 2004 350 1220-1234. (doi:10.1056/ NEJMra025261)
2. Misra A & Garg A. Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature. Medicine 2003 82 129-146. (doi:10.1097/ 00005792-200303000-00007)
3. Cauble MS, Gilroy R, Sorrell M.F., Mailliard ME, Sudan DL, Anderson JC, Wisecarver JL, Balakrishnan S & Larsen JL. Lipoatrophic diabetes and end-stage liver disease secondary to nonalcoholic steatohepatitis with recurrence after liver transplantation. Transplantation 2001 71 892-895. (doi:10.1097/ 00007890-200104150-00012)
4. Oral EA, Simha V, Ruiz E., Andewelt A, Premkumar A, Snell P., Wagner AJ, DePaoli AM, Reitman ML, Taylor SI et al. Leptin-replacement therapy for lipodystrophy. New England Journal of Medicine 2002 346 570-578. (doi:10.1056/NEJMoa012437)
5. Simha V, Szczepaniak LS, Wagner A.J., DePaoli AM & Garg A. Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy. Diabetes Care 2003 26 30-35. (doi:10.2337/diacare.26.1.30)
6. Petersen KF, Oral EA, Dufour S, Befroy D., Ariyan C, Yu C, Cline G.W., DePaoli AM, Taylor SI, Gorden P et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. Journal of Clinical Investigation 2002 109 1345-1350.
7. Javor ED, Cochran EK, Musso C, Young J.R., Depaoli AM & Gorden P. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes 2005 54 1994-2002. (doi:10.2337/diabetes.54.7.1994)
8. Javor ED, Ghany MG, Cochran E.K., Oral EA, DePaoli AM, Premkumar A, Kleiner DE & Gorden P. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology 2005 41 753-760. (doi:10.1002/hep.20672)
9. Simha V, Subramanyam L, Szczepaniak L., Quittner C, Adams-Huet B, Snell P & Garg A. Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety. Journal of Clinical Endocrinology and Metabolism 2011 97 785-792. (doi:10.1210/jc.2011-2229)
10. Haque WA, Shimomura I, Matsuzawa Y & Garg A. Serum adiponectin and leptin levels in patients with lipodystrophies. Journal of Clinical Endocrinology and Metabolism 2002 87 2395. (doi:10.1210/jc.87.5.2395)
11. Wong SP, Huda M, English P., Bargiotta A, Wilding JP, Johnson A, Corrall R & Pinkney JH. Adipokines and the insulin resistance syndrome in familial partial lipodystrophy caused by a mutation in lamin A/C. Diabetologia 2005 48 2641-2649. (doi:10.1007/ s00125-005-0038-x)
12. Nguyen TA & Sanyal AJ. Pathophysiology guided treatment of nonalcoholic steatohepatitis. Journal of Gastroenterology and Hepatology 2012 27 (Suppl 2) 58-64. (doi:10.1111/j.1440-1746.2011.07018.x)
13. Leuschner UF, Lindenthal B, Herrmann G., Arnold JC, Rossle M, Cordes HJ, Zeuzem S, Hein J & Berg T. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 2010 52472-479. (doi:10.1002/hep.23727)
14. Sanyal AJ, Chalasani N, Kowdley K.V., McCullough A., Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A et al. Pioglitazone, vitamin E, or Placebo for nonalcoholic for nonalcoholic steatohepatitis. New England Journal of Medicine 2010 362 1675-1685. (doi:10.1056/NEJMoa0907929)
15. Angelico F, Burattin M, Alessandri C., Del Ben M & Lirussi F. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database of Systematic Reviews 2007 (Article ID CD005166). (doi:10.1002/ 14651858.CD005166)
16. Abdelmalek MF, Sanderson SO, Angulo P, Soldevila-Pico C, Liu C., Peter J, Keach J, Cave M., Chen T, McClain CJ et al. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology 2009 50 1818-1826. (doi:10.1002/ hep.23239)
17. Merat S, Malekzadeh R, Sohrabi M.R., Sotoudeh M., Rakhshani N, Sohrabpour AA & Naserimoghadam S. Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study. Journal of Hepatology 2003 38 414-418. (doi:10.1016/S0168-8278(02)00441-5)
18. Miller ER III, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ & Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Annals of Internal Medicine 2005 142 37-46.
19. Einarsson K, Hellstrom K & Kallner M. Effect of cholic acid feeding on bile acid kinetics and neutral fecal steroid excretion in hyperlipoproteinemia (types II and IV). Metabolism 1974 23 863-873. (doi:10.1016/0026-0495(74)90120-6)
20. Angelin B & Leijd B. Effects of cholic acid on the metabolism of endogenous plasma triglyceride and on biliary lipid composition in hyperlipoproteinemia. Journal of Lipid Research 1980 21 1-9.
21. Fujino T, Une M, Imanaka T., Inoue K & Nishimaki-Mogami T. Structure-activity relationship of bile acids and bile acid analogs in regard to FXR activation. Journal of Lipid Research 2004 45 132-138. (doi:10.1194/jlr. M300215-JLR200)
22. Watanabe M, Houten SM, Wang L, Moschetta A., Mangelsdorf DJ, Heyman RA, Moore DD & Auwerx J. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. Journal of Clinical Investigation 2004 113 1408-1418.
23. Cipriani S, Mencarelli A, Palladino G & Fiorucci S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. Journal of Lipid Research 2010 51 771-784. (doi:10.1194/jlr.M001602)
24. Szczepaniak LS, Nurenberg P, Leonard D., Browning JD, Reingold JS, Grundy S, Hobbs HH & Dobbins RL. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. American Journal of Physiology. Endocrinology and Metabolism 2005 288 E462-E468. (doi:10.1152/ajpendo.00064.2004)
25. Gabbi C, Bertolotti M, Anzivino C., Macchioni D, Del Puppo M, Ricchi M, Carubbi F., Tagliafico E, Romagnoli D, Odoardi MR et al. Effects of bile duct ligation and cholic acid treatment on fatty liver in two rat models of non-alcoholic fatty liver disease. Digestive and Liver Disease 2012 44 1018-1026.
26. Adorini L, Pruzanski M & Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discovery Today 2012 17 988-997. (doi:10.1016/j.drudis.2012.05.012)
27. Zhang Y & Edwards PA. FXR signaling in metabolic disease. FEBS Letters 2008 582 10-18. (doi:10.1016/j.febslet.2007.11.015)
28. Sinal CJ, Tohkin M, Miyata M., Ward JM, Lambert G & Gonzalez FJ. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000 102 731-744. (doi:10.1016/S0092-8674(00)00062-3)
29. Zhang S, Wang J, Liu Q & Harnish DC. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. Journal of Hepatology 2009 51 380-388. (doi:10.1016/j.jhep. 2009.03.025)
30. Kast HR, Nguyen CM, Sinal C.J., Jones SA, Laffitte BA, Reue K, Gonzalez F.J., Willson TM & Edwards PA. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. Molecular Endocrinology 2001 15 1720-1728. (doi:10.1210/ me.15.10.1720)
31. Duran-Sandoval D., Cariou B, Percevault F., Hennuyer N, Grefhorst A, van Dijk TH, Gonzalez FJ, Fruchart JC, Kuipers F & Staels B. The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. Journal of Biological Chemistry 2005 280 29971-29979. (doi:10.1074/ jbc.M501931200)
32. Woollett LA, Buckley DD, Yao L, Jones P.J., Granholm NA, Tolley EA, Tso P & Heubi JE. Cholic acid supplementation enhances cholesterol absorption in humans. Gastroenterology 2004 126 724-731. (doi:10.1053/j.gastro.2003.11.058)
33. Carulli N, Ponz de Leon M, Podda M, Zuin M, Strata A, Frigerio G & Digrisolo A. Chenodeoxycholic acid and ursodeoxycholic acid effects in endogenous hypertriglyceridemias. Journal of Clinical Pharmacology 1981 21 436-442. (doi:10.1002/j.1552-4604.1981.tb01746.x)
34. Camarri E, Marcolongo R & Fici F. Hypotriglyceridemic effect of chenodeoxycholic acid after a short time of administration. International Journal of Clinical Pharmacology and Biopharmacy 1978 16 527-528.
35. Camarri E, Fici F & Marcolongo R. Influence of chenodeoxycholic acid on serum triglycerides in patients with primary hypertri-glyceridemia. International Journal of Clinical Pharmacology and Biopharmacy 1978 16 523-526.
36. Bateson MC, Maclean D, Evans JR & Bouchier IA. Chenode-oxycholic acid therapy for hypertriglyceridaemia in men. British Journal of Clinical Pharmacology 1978 5 249-254. (doi:10.1111/ j.1365-2125.1978.tb01632.x)
37. Schoenfield LJ & Lachin JM. Chenodiol (chenodeoxycholic acid) for dissolution of gallstones: the National Cooperative Gallstone Study. A controlled trial of efficacy and safety. Annals of Internal Medicine 1981 95 257-282.
38. Setchell KD & Heubi JE. Defects in bile acid biosynthesis - diagnosis and treatment. Journal of Pediatric Gastroenterology and Nutrition 2006 43 (Suppl 1) S17-S22. (doi:10.1097/01.mpg.0000226 386.79483.7b)
39. Adler RD, Bennion LJ, Duane WC & Grundy SM. Effects of low dose chenodeoxycholic acid feeding on biliary lipid metabolism. Gastroenterology 1975 68 326-334.
40. Thistle JL & Hofmann AF. Efficacy and specificity of chenodeoxy-cholic acid therapy for dissolving gallstones. New England Journal of Medicine 1973 289 655-659. (doi:10.1056/NEJM1973092 72891303)
41. Toouli J, Jablonski P & Watts JM. Gallstone dissolution in man using cholic acid and lecithin. Lancet 1975 2 1124-1126. (doi:10.1016/S0140-6736(75) 91008-9)
42. LaRusso NF, Hoffman NE, Hofmann A.F., Northfield TC & Thistle JL. Effect of primary bile acid ingestion on bile acid metabolism and biliary lipid secretion in gallstone patients. Gastroenterology 1975 69 1301-1314.
43. Thistle JL & Schoenfield LJ. Induced alterations incomposition of bile of persons having cholelithiasis. Gastroenterology 1971 61488-496.
44. Sama C & LaRusso NF. Effect of deoxycholic, chenodeoxycholic, and cholic acids on intestinal absorption of cholesterol in humans. Mayo Clinic Proceedings 1982 57 44-50.
45. Agarwal AK, Sukumaran S, Cortes V.A., Tunison K., Mizrachi D, Sankella S, Gerard R.D., Horton JD & Garg A. Human 1-acylglycerol-3-phosphate O-acyltransferase isoforms 1 and 2: biochemical characterization and inability to rescue hepatic steatosis in Agpat2(K/K) gene lipodystrophic mice. Journal of Biological Chemistry 2011 286 37676-37691. (doi:10.1074/jbc. M111.250449)
46. Lindor KD. Farnesoid X receptor agonists for primary biliary cirrhosis. Current Opinion in Gastroenterology 2011 27 285-288. (doi:10.1097/MOG. 0b013e32834452c8)